420 Magazine Background

Cannabis Drug Firm GW Pharmaceuticals Taps Wall Street For $252 Million

Katelyn Baker

Well-Known Member
Wall Street's strait-laced Republican bankers may have strong personal views on the legalisation of cannabis, but they seem to have no qualms about cashing in on America's marijuana revolution.

GW Pharmaceuticals, London's own play on the increasing use of weed for medicinal purposes, has opted to raise $252 million on Nasdaq, with Morgan Stanley, Bank of America Merrill Lynch and Goldman Sachs, three of the US's biggest banks, leading the fundraiser as joint bookrunners.

Cambridge-based GW, whose main listing is on AIM but which allows US investors to trade American Depository Shares on Nasdaq, is issuing the new shares at $90 each, below yesterday's $97.10 price at the closing bell.

The minor discount caused the AIM shares in GW, the junior market's third-largest company with a value of £1.6 billion, to slide 15.5p, or 2.5%, to 597.5p.

It is among the hallowed "ten-baggers" on the junior market, having risen tenfold in just three years.

With the Bank of England meeting tomorrow for the first time since the EU referendum, investors enjoyed some welcome stability in the markets, with yesterday's small dip followed by a tiny move higher today as the FTSE 100 rose 3.29 points to 6683.98.

A surge in industrial metals prices, especially copper, lifted the mining sector, raising Antofagasta 16.64p to 502.64p, and helping to offset a shaky day for housebuilders on the back of Barratt Developments' downbeat trading statement.

Entertainment One, the production company behind The Office spin-off film David Brent: Life on the Road, released next month, succumbed to profit taking, tumbling 6.7p to 194.8p, following revised takeover chatter.

Playtech surged 34p, or 4%, to 850p, valuing Teddy Sagi's gambling software firm at £2.76 billion, after the €138 million takeover of Best Gaming Technology, whose software runs self-service betting terminals. The deal represents Playtech's first move into betting shops.

A strong first-half performance from cars dealer Marshall Motors helped the shares accelerate 1.38p to 154.88p.

Meanwhile, it was revealed Mike Lynch, the controversial founder of Autonomy, sold £1.3 million of shares yesterday in AIM-listed RhythmOne, formerly blinkx, which was spun out of his former tech giant. RhythmOne shares fell 1.7p to 30.55p.

News Moderator: Katelyn Baker 420 MAGAZINE ®
Full Article: Cannabis Drug Firm GW Pharmaceuticals Taps Wall Street For $252 Million
Author: Jamie Nimmo
Contact: Evening Standard
Photo Credit: Reuters
Website: Evening Standard
Top Bottom